-transparent.png){kind=logo}
The antineoplastic activities of ASTA Z 7557 and cyclophosphamide (CPA) were compared in advanced transplanted AKR lymphoma by determining the optimal dose using single dose and twofold applications. Autochthonous DMBA-induced leukemias and MNU-induced mammary carcinomas were treated with fractionated doses over 3 and 5 weeks, respectively. In the respective optimal dosages ASTA Z 7557 exhibited an antitumor effect comparable to that of CPA in all three models. The results obtained by treatment of the autochthonous models indicate that Z 7557 seems to have advantages over CPA in the treatment of malignancies with impaired bone marrow function as for instance acute leukemias and in fractionated dose schedules.
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
January 1984,
Investigational new drugs,
W J Zeller, and
M R Berger, and
R Matys, and
J Schuhmacher
June 1989,
Experimental hematology,
